Library

Exclusive Interview with:

anna bunin

Anna Bunin
Expert Speaker, PREDiCT: Tumor Models
Associate Director - Immunology, Kleo Pharmaceuticals Inc.

With the rise of novel molecules and immunotherapies, being able to optimize and validate a suitable preclinical model will help advance drug candidates into clinics. Kleo Pharmaceuticals, an up-and-coming biotech with proprietary platform specialized in NK cells and bispecific medium sized– antibody recruiting molecules (ARMs), has developed a unique toolbox to enable this  advancement. I have caught up with their Associate Director – Immunology, Anna Bunin, for her insight and journey in this space.

Topics covered in the interview:

 

  1. The shift in preclinical drug discovery – particularly the utilization of data-driven models to support preclinical assessment
  2. The lack of animal models for preclinical evaluation: advice for pharma and biotech
  3. Using human target knock-in mouse model for IO drug discovery
  4. Selecting the right models during drug discovery

Exclusive Interview with:

Davy Ouyang Speaker Photo PREDiCT Tumor Models Boston

Davy Ouyang
Expert Speaker, PREDiCT: Tumor Models
Executive Director, Cancer Pharmacology, Crown Bioscience

Crown Bioscience is the leading preclinical CRO with expertise in the disease areas of oncology, inflammation, and metabolic disease. They are known for the breadth and quality of their in vitro and in vivo models. Ahead of the PREDiCT: 7th Annual Tumor Models Boston Summit in July, we have caught up with Davy Ouyang, Executive Director at Crown Bioscience to hear his thoughts and insights in the fast evolving oncology space!

Topics covered in the interview:

 

  1. The shift in preclinical drug discovery – particularly the utilization of data-driven models to support preclinical assessment
  2. The lack of animal models for preclinical evaluation: advice for pharma and biotech
  3. Using human target knock-in mouse model for IO drug discovery
  4. Selecting the right models during drug discovery

Exclusive Past Presentation by:

Shiva Kazerounian Berg Scienist Speaker photo

Dr Shiva Kazerounian
Expert Speaker, PREDiCT: Tumor Models
Principal Scientist, In Vivo Pharmacology Lead, Berg Pharma

Berg Pharma logo

"Challenges, Insights, and Future Directions

for Experimental Models in Cancer Immunotherapy"

Outline:

  • Introduction to Cancer Immunotherapy
  • Mouse Models for Cancer Immunotherapy
  • Managing Outsourced Vendors Effectively